 Antithrombin III supplementation reduces requirement platelet loss hemodialysis patients fulminant hepatic failure Previous studies antithrombin III levels low fulminant hepatic failure heparin kinetics abnormal control heparinization difficult hemodialysis patients risk study trial antithrombin III supplementation heparin activity occurrence bleeding platelet count activation hemodialysis patients fulminant hepatic failure treated group patients units antithrombin III hemodialysis Antithrombin III supplementation antithrombin III levels hemodialysis prelevels U/ml S.E hr U/ml control prelevels U/ml hr U/ml Total heparin usage antithrombin III supplementation median range control group median range Blood heparin level antifactor Xa activity initial bolus antithrombin III-supplemented subjects U/ml U/ml control group significant reduction platelet count control patients hr antithrombin III patients hr release platelet-specific protein beta-thromboglobulin patients groups minor bleeding vascular access sites first hemodialysis